C4 Therapeutics Inc Stock News

CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.76 per share a year ago.

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

C4 Therapeutics, Inc. (CCCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

From a technical perspective, C4 Therapeutics, Inc. (CCCC) is looking like an interesting pick, as it just reached a key level of support. CCCC's 50-day simple moving average crossed above its 200-day

C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

As the market soars to new heights, with capital fast flowing back into the small-cap, more speculative, and traditionally risky investments and sectors, C4 Therapeutics NASDAQ: CCCC has become the la

C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.

The last Fed meeting of the year is upon us, as those record highs for stock markets just keep coming. Can the Fed keep those fires burning?

C4 Therapeutics Inc shares surged 93% to $2.28 in early trading on Tuesday after the clinical-stage biopharmaceutical company announced an exclusive license and collaboration agreement with Merck to d

C4 Therapeutics (NASDAQ: CCCC ) stock is heading higher on Tuesday as investors in the clinical-stage biopharmaceutical company celebrate a new license and research collaboration with Merck (NYSE: MRK

WATERTOWN, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science t

C4 Therapeutics, Inc. (CCCC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen

C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.65 per share a year ago.